JP2012510990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510990A5 JP2012510990A5 JP2011539512A JP2011539512A JP2012510990A5 JP 2012510990 A5 JP2012510990 A5 JP 2012510990A5 JP 2011539512 A JP2011539512 A JP 2011539512A JP 2011539512 A JP2011539512 A JP 2011539512A JP 2012510990 A5 JP2012510990 A5 JP 2012510990A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1c(*c2nc(-c(ccc(Cl)c3)c3NC(C3)=S)c3cn2)ccc(NC2CCOCC2)n1 Chemical compound Cc1c(*c2nc(-c(ccc(Cl)c3)c3NC(C3)=S)c3cn2)ccc(NC2CCOCC2)n1 0.000 description 6
- GRRYJNGWMGBROD-UHFFFAOYSA-N CCN(CC1)C(C)CN1c1cc(Nc2nc(-c(ccc(C(F)(F)F)c3)c3NC(C3)=S)c3cn2)c(C)nc1 Chemical compound CCN(CC1)C(C)CN1c1cc(Nc2nc(-c(ccc(C(F)(F)F)c3)c3NC(C3)=S)c3cn2)c(C)nc1 GRRYJNGWMGBROD-UHFFFAOYSA-N 0.000 description 2
- IQTBRHFDWMPQAI-UHFFFAOYSA-N CN1CCN(CCc2cc(Nc3nc(-c(ccc(Cl)c4)c4NC(C4)=S)c4cn3)cnc2)CC1 Chemical compound CN1CCN(CCc2cc(Nc3nc(-c(ccc(Cl)c4)c4NC(C4)=S)c4cn3)cnc2)CC1 IQTBRHFDWMPQAI-UHFFFAOYSA-N 0.000 description 2
- SDVFANGFMOTNCA-UHFFFAOYSA-N Cc(cc1)nc(C)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(cc1)nc(C)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 SDVFANGFMOTNCA-UHFFFAOYSA-N 0.000 description 2
- SDXRJLLEPPVNIZ-UHFFFAOYSA-N Cc(nc(cc1)C(NCCN2CCOCC2)=O)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)C(NCCN2CCOCC2)=O)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 SDXRJLLEPPVNIZ-UHFFFAOYSA-N 0.000 description 2
- PYHWTNXHCDOHTE-UHFFFAOYSA-N Cc1ncc(CCCO)cc1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc1ncc(CCCO)cc1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 PYHWTNXHCDOHTE-UHFFFAOYSA-N 0.000 description 2
- JFUYOPITVGVJRR-UHFFFAOYSA-O CC(C1)C(C(F)(F)F)=CC(NC(C2)=S)=C1c1c2cnc(Nc(cc2)c(C)nc2N(CCC2)CC2[NH2+]C)n1 Chemical compound CC(C1)C(C(F)(F)F)=CC(NC(C2)=S)=C1c1c2cnc(Nc(cc2)c(C)nc2N(CCC2)CC2[NH2+]C)n1 JFUYOPITVGVJRR-UHFFFAOYSA-O 0.000 description 1
- ZDRNXZBXERHNLN-UHFFFAOYSA-N CC1OCCN(CCc2cnc(C)c(Nc3nc(-c(ccc(Cl)c4)c4NC(C4)=S)c4cn3)c2)C1 Chemical compound CC1OCCN(CCc2cnc(C)c(Nc3nc(-c(ccc(Cl)c4)c4NC(C4)=S)c4cn3)c2)C1 ZDRNXZBXERHNLN-UHFFFAOYSA-N 0.000 description 1
- NFNZCYTYVWNEFB-UHFFFAOYSA-N CCN(C)CCCc1cc(Nc2nc(-c(cc(C(F)(F)F)cc3)c3NC(C3)=S)c3cn2)c(C)nc1 Chemical compound CCN(C)CCCc1cc(Nc2nc(-c(cc(C(F)(F)F)cc3)c3NC(C3)=S)c3cn2)c(C)nc1 NFNZCYTYVWNEFB-UHFFFAOYSA-N 0.000 description 1
- YLINSJANNKWGRA-UHFFFAOYSA-N CCN(CC1)CCN1c1cc(Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=S)c3cn2)cnc1 Chemical compound CCN(CC1)CCN1c1cc(Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=S)c3cn2)cnc1 YLINSJANNKWGRA-UHFFFAOYSA-N 0.000 description 1
- RELZKMVLKISHNZ-UHFFFAOYSA-N CCOc1ncc(CCCN(C)C)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound CCOc1ncc(CCCN(C)C)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 RELZKMVLKISHNZ-UHFFFAOYSA-N 0.000 description 1
- FAGHDUMHZMKMTN-UHFFFAOYSA-N CCc(cc1)cc(NC(C2)=S)c1-c1c2cnc(Nc2c(CC)ncc(CCCNC)c2)n1 Chemical compound CCc(cc1)cc(NC(C2)=S)c1-c1c2cnc(Nc2c(CC)ncc(CCCNC)c2)n1 FAGHDUMHZMKMTN-UHFFFAOYSA-N 0.000 description 1
- XIKNZYDIXGJELH-UHFFFAOYSA-N CCc1ncc(CCCNC)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound CCc1ncc(CCCNC)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 XIKNZYDIXGJELH-UHFFFAOYSA-N 0.000 description 1
- LXFFXVXRPOHCGI-UHFFFAOYSA-N CCc1ncc(CCN2CCCCC2)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound CCc1ncc(CCN2CCCCC2)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 LXFFXVXRPOHCGI-UHFFFAOYSA-N 0.000 description 1
- MROPSWNXXATBDY-UHFFFAOYSA-N Cc(ccnc1C)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ccnc1C)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 MROPSWNXXATBDY-UHFFFAOYSA-N 0.000 description 1
- SFRZXRZXLZCTPB-UHFFFAOYSA-N Cc(nc(CCC(C1)N(C)C)c1c1)c1Nc1ncc(CC(Nc2cc(Cl)ccc2-2)=S)c-2n1 Chemical compound Cc(nc(CCC(C1)N(C)C)c1c1)c1Nc1ncc(CC(Nc2cc(Cl)ccc2-2)=S)c-2n1 SFRZXRZXLZCTPB-UHFFFAOYSA-N 0.000 description 1
- DQFXDEDHJKQCCY-UHFFFAOYSA-N Cc(nc(CCCN(C)C)cc1)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(CCCN(C)C)cc1)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 DQFXDEDHJKQCCY-UHFFFAOYSA-N 0.000 description 1
- QCGVVACIRWZIMA-UHFFFAOYSA-O Cc(nc(cc1)C(NCC[NH2+]C)=O)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)C(NCC[NH2+]C)=O)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 QCGVVACIRWZIMA-UHFFFAOYSA-O 0.000 description 1
- XOJIAGYTZJUHQD-UHFFFAOYSA-N Cc(nc(cc1)N(C)C2CN(C)CC2)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)N(C)C2CN(C)CC2)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 XOJIAGYTZJUHQD-UHFFFAOYSA-N 0.000 description 1
- GWDCXAMSEXXXFQ-UHFFFAOYSA-N Cc(nc(cc1)N(C)C2CN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC2SC2C2)c2cn1 Chemical compound Cc(nc(cc1)N(C)C2CN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC2SC2C2)c2cn1 GWDCXAMSEXXXFQ-UHFFFAOYSA-N 0.000 description 1
- HBFUUQUEFJBPHL-UHFFFAOYSA-N Cc(nc(cc1)N(CCC2)CC2N(C)C)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)N(CCC2)CC2N(C)C)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 HBFUUQUEFJBPHL-UHFFFAOYSA-N 0.000 description 1
- IJVYGVFXBAHWEG-UHFFFAOYSA-N Cc(nc(cc1)NC2CCN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)NC2CCN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 IJVYGVFXBAHWEG-UHFFFAOYSA-N 0.000 description 1
- JGPVMCRVZAGQIF-UHFFFAOYSA-N Cc(nc(cc1)NCC2CCN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)NCC2CCN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 JGPVMCRVZAGQIF-UHFFFAOYSA-N 0.000 description 1
- ONTJWGOCDOVRPU-UHFFFAOYSA-N Cc(nc(cc1)NCCCN(C)C)c1NC(N(C)C=C1C2)N=C1c(ccc(C(F)(F)F)c1)c1NC2=S Chemical compound Cc(nc(cc1)NCCCN(C)C)c1NC(N(C)C=C1C2)N=C1c(ccc(C(F)(F)F)c1)c1NC2=S ONTJWGOCDOVRPU-UHFFFAOYSA-N 0.000 description 1
- NCHNKYZZBIIJMP-UHFFFAOYSA-N Cc(nc(cc1)NCCCN(C)C)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)NCCCN(C)C)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 NCHNKYZZBIIJMP-UHFFFAOYSA-N 0.000 description 1
- VKYHGPOZCLPGFR-UHFFFAOYSA-N Cc(nc(cc1)NCCCNC)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)NCCCNC)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 VKYHGPOZCLPGFR-UHFFFAOYSA-N 0.000 description 1
- YICUEIGJCSBDQP-UHFFFAOYSA-N Cc(nc(cc1)NCCN(C)C)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)NCCN(C)C)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 YICUEIGJCSBDQP-UHFFFAOYSA-N 0.000 description 1
- LFPPNRYZCYNSGD-UHFFFAOYSA-N Cc(nc(cc1)OC2CCN(C)CC2)c1NC[n+]([n-]cc1C2)c1-c(ccc(Cl)c1)c1NC2=S Chemical compound Cc(nc(cc1)OC2CCN(C)CC2)c1NC[n+]([n-]cc1C2)c1-c(ccc(Cl)c1)c1NC2=S LFPPNRYZCYNSGD-UHFFFAOYSA-N 0.000 description 1
- NYOIBYMTSVEYSG-UHFFFAOYSA-N Cc(nc(cc1)OC2CCN(C)CC2)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)OC2CCN(C)CC2)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 NYOIBYMTSVEYSG-UHFFFAOYSA-N 0.000 description 1
- ZLDDSCWQYDKNRR-UHFFFAOYSA-N Cc(nc(cc1)OC2CCN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)OC2CCN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 ZLDDSCWQYDKNRR-UHFFFAOYSA-N 0.000 description 1
- WBNWWFCCQJSJIJ-UHFFFAOYSA-O Cc(nc(cc1)[NH2+]C2CN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc(cc1)[NH2+]C2CN(C)CC2)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 WBNWWFCCQJSJIJ-UHFFFAOYSA-O 0.000 description 1
- OKILHZZQVKFDSZ-UHFFFAOYSA-N Cc(nc1)c(CCCN(C)C)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc1)c(CCCN(C)C)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 OKILHZZQVKFDSZ-UHFFFAOYSA-N 0.000 description 1
- QGWMENHEYDEMJB-UHFFFAOYSA-N Cc(nc1C)c(CCCN(C)C)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(nc1C)c(CCCN(C)C)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 QGWMENHEYDEMJB-UHFFFAOYSA-N 0.000 description 1
- XGZCYYPMEGHTEH-UHFFFAOYSA-N Cc(ncc(CCCCN(C)C)c1)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCCCN(C)C)c1)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 XGZCYYPMEGHTEH-UHFFFAOYSA-N 0.000 description 1
- XQLWQOSLZQPJMV-UHFFFAOYSA-N Cc(ncc(CCCN(C)C)c1)c1Nc1nc(-c(ccc(C2CC2)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCCN(C)C)c1)c1Nc1nc(-c(ccc(C2CC2)c2)c2NC(C2)=S)c2cn1 XQLWQOSLZQPJMV-UHFFFAOYSA-N 0.000 description 1
- JXWXYAHEPUNZFM-QHCPKHFHSA-N Cc(ncc(CCCN(C)C)c1)c1Nc1nc(-c(ccc([C@H]2[O](C)C2)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCCN(C)C)c1)c1Nc1nc(-c(ccc([C@H]2[O](C)C2)c2)c2NC(C2)=S)c2cn1 JXWXYAHEPUNZFM-QHCPKHFHSA-N 0.000 description 1
- YCPQURUPHSVLEG-UHFFFAOYSA-N Cc(ncc(CCCNC)c1)c1Nc1nc(-c(cc(CCCN(C)C)c(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCCNC)c1)c1Nc1nc(-c(cc(CCCN(C)C)c(Cl)c2)c2NC(C2)=S)c2cn1 YCPQURUPHSVLEG-UHFFFAOYSA-N 0.000 description 1
- YMHULQMMSMDAON-UHFFFAOYSA-N Cc(ncc(CCN(C)C)c1)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCN(C)C)c1)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 YMHULQMMSMDAON-UHFFFAOYSA-N 0.000 description 1
- PGGPCOJBTWTKHF-UHFFFAOYSA-N Cc(ncc(CCN(CC1)CCC1N(C)C)c1)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCN(CC1)CCC1N(C)C)c1)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 PGGPCOJBTWTKHF-UHFFFAOYSA-N 0.000 description 1
- ZTVKROOUYYNFMG-UHFFFAOYSA-N Cc(ncc(CCN(CC1)CCC1NC)c1)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCN(CC1)CCC1NC)c1)c1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 ZTVKROOUYYNFMG-UHFFFAOYSA-N 0.000 description 1
- JTWYWZKUDAELGY-UHFFFAOYSA-N Cc(ncc(CCN1CCN(C)CC1)c1)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCN1CCN(C)CC1)c1)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 JTWYWZKUDAELGY-UHFFFAOYSA-N 0.000 description 1
- XBHFEKGGSHWUDE-UHFFFAOYSA-N Cc(ncc(CCN1CCNCC1)c1)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(CCN1CCNCC1)c1)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 XBHFEKGGSHWUDE-UHFFFAOYSA-N 0.000 description 1
- DCXHYGFUSDJWQZ-UHFFFAOYSA-N Cc(ncc(N1CCN(C)CC1)c1)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc(ncc(N1CCN(C)CC1)c1)c1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 DCXHYGFUSDJWQZ-UHFFFAOYSA-N 0.000 description 1
- IPWRQNQYUQQCMH-UHFFFAOYSA-O Cc(nccc1)c1Nc1ncc(CC(Nc2c-3cc(CCC[NH2+]C)c(Cl)c2)=S)c-3n1 Chemical compound Cc(nccc1)c1Nc1ncc(CC(Nc2c-3cc(CCC[NH2+]C)c(Cl)c2)=S)c-3n1 IPWRQNQYUQQCMH-UHFFFAOYSA-O 0.000 description 1
- RKAHKXKQFNDCBK-UHFFFAOYSA-N Cc1nc(CC(CC2)NC)c2cc1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc1nc(CC(CC2)NC)c2cc1Nc1nc(-c(ccc(C(F)(F)F)c2)c2NC(C2)=S)c2cn1 RKAHKXKQFNDCBK-UHFFFAOYSA-N 0.000 description 1
- ZSJBPGXPMZMWDU-UHFFFAOYSA-N Cc1ncc(CCCN(C)C)cc1Nc1nc(-c(ccc(OC)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc1ncc(CCCN(C)C)cc1Nc1nc(-c(ccc(OC)c2)c2NC(C2)=S)c2cn1 ZSJBPGXPMZMWDU-UHFFFAOYSA-N 0.000 description 1
- OJWPRRYPOYOCDZ-UHFFFAOYSA-N Cc1ncc(CCN2CCCCC2)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 Chemical compound Cc1ncc(CCN2CCCCC2)cc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=S)c2cn1 OJWPRRYPOYOCDZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20094508P | 2008-12-05 | 2008-12-05 | |
| US61/200,945 | 2008-12-05 | ||
| PCT/US2009/006391 WO2010065134A1 (en) | 2008-12-05 | 2009-12-04 | 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014153744A Division JP2014221824A (ja) | 2008-12-05 | 2014-07-29 | Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510990A JP2012510990A (ja) | 2012-05-17 |
| JP2012510990A5 true JP2012510990A5 (enExample) | 2013-01-31 |
| JP5684719B2 JP5684719B2 (ja) | 2015-03-18 |
Family
ID=42076993
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539512A Expired - Fee Related JP5684719B2 (ja) | 2008-12-05 | 2009-12-04 | Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン |
| JP2014153744A Withdrawn JP2014221824A (ja) | 2008-12-05 | 2014-07-29 | Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014153744A Withdrawn JP2014221824A (ja) | 2008-12-05 | 2014-07-29 | Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US7998952B2 (enExample) |
| EP (1) | EP2373657B1 (enExample) |
| JP (2) | JP5684719B2 (enExample) |
| AR (1) | AR074487A1 (enExample) |
| TW (1) | TW201026703A (enExample) |
| UY (1) | UY32303A (enExample) |
| WO (1) | WO2010065134A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1799684B1 (en) * | 2004-10-04 | 2014-12-03 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| CN111763170B (zh) * | 2020-07-10 | 2022-03-18 | 江苏豪森药业集团有限公司 | 氟马替尼中间体的制备方法 |
| CN115197195A (zh) * | 2021-04-09 | 2022-10-18 | 江苏豪森药业集团有限公司 | 氟马替尼中间体的制备方法 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06172355A (ja) | 1992-04-14 | 1994-06-21 | Mect Corp | ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤 |
| DE4332168A1 (de) * | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5686445A (en) * | 1993-07-29 | 1997-11-11 | American Cyanamid Company | Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists |
| US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| US5925635A (en) * | 1996-04-17 | 1999-07-20 | Dupont Pharmaceuticals Company | N-(amidinophenyl) cyclourea analogs as factor XA inhibitors |
| WO1997047601A1 (en) | 1996-06-11 | 1997-12-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and medicinal uses thereof |
| AU3296497A (en) | 1996-06-13 | 1998-01-07 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| AU5330698A (en) * | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) * | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| FR2804959B1 (fr) * | 2000-02-15 | 2006-04-28 | Centre Nat Rech Scient | Utilisation de derives de paullones pour la fabrication de medicaments |
| US6369222B1 (en) | 2000-07-18 | 2002-04-09 | Hoffmann-La Roche Inc. | mGluR antagonists and a method for their synthesis |
| US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US7105667B2 (en) * | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| US6686352B2 (en) * | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| PL378116A1 (pl) | 2003-02-27 | 2006-03-06 | Abbott Laboratories | Heterocykliczne inhibitory kinazy |
| ES2331245T3 (es) * | 2003-07-21 | 2009-12-28 | Pfizer Products Inc. | Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina. |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| KR101792651B1 (ko) * | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| EP1799684B1 (en) * | 2004-10-04 | 2014-12-03 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
| PE20070171A1 (es) | 2005-06-30 | 2007-03-08 | Boehringer Ingelheim Int | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
-
2009
- 2009-12-04 US US12/631,144 patent/US7998952B2/en active Active
- 2009-12-04 EP EP09795577.7A patent/EP2373657B1/en active Active
- 2009-12-04 TW TW098141596A patent/TW201026703A/zh unknown
- 2009-12-04 WO PCT/US2009/006391 patent/WO2010065134A1/en not_active Ceased
- 2009-12-04 JP JP2011539512A patent/JP5684719B2/ja not_active Expired - Fee Related
- 2009-12-04 AR ARP090104716A patent/AR074487A1/es unknown
- 2009-12-07 UY UY0001032303A patent/UY32303A/es not_active Application Discontinuation
-
2011
- 2011-06-30 US US13/173,161 patent/US8268992B2/en active Active
-
2012
- 2012-08-09 US US13/570,486 patent/US8507667B2/en not_active Expired - Fee Related
- 2012-08-09 US US13/570,518 patent/US20120302551A1/en not_active Abandoned
-
2013
- 2013-11-07 US US14/074,506 patent/US20140194410A1/en not_active Abandoned
-
2014
- 2014-07-29 JP JP2014153744A patent/JP2014221824A/ja not_active Withdrawn
- 2014-10-29 US US14/526,699 patent/US20150175542A1/en not_active Abandoned